Assembly Biosciences (ASMB) Net Equity Issued and Repurchased (2011 - 2025)

Assembly Biosciences' Net Equity Issued and Repurchased history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $1.9 million in Q1 2025; TTM through Dec 2025 was $1.9 million, a 5.32% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 5.32% from the prior year.
• Net Equity Issued and Repurchased slipped to $1.9 million in Q1 2025 per ASMB's latest filing, from $2.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $34.1 million in Q1 2021 and bottomed at $54000.0 in Q2 2023.
• The 5-year median for Net Equity Issued and Repurchased is $2.6 million (2021), against an average of $6.8 million.
• Across the five-year window, Net Equity Issued and Repurchased slumped 52.33% in 2021 and slumped 87.5% in 2022, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $2.6 million in 2021, then slumped by 87.5% to $325000.0 in 2022, then tumbled by 83.38% to $54000.0 in 2023, then soared by 3659.26% to $2.0 million in 2024, then retreated by 5.32% to $1.9 million in 2025.
• Per Business Quant, the three latest ASMB Net Equity Issued and Repurchased figures stand at $1.9 million (Q1 2025), $2.0 million (Q4 2024), and $54000.0 (Q2 2023).